ITP showdown: daily pill vs IV infusion in major new trial
Disease control
Not yet recruiting
This phase 3 trial will compare two second-line treatments for immune thrombocytopenia (ITP), a condition where the immune system destroys platelets, causing bleeding risk. About 220 adults who didn't respond to steroids will be randomly assigned to take avatrombopag (a daily pil…
Phase: PHASE3 • Sponsor: Ostfold Hospital Trust • Aim: Disease control
Last updated Jun 26, 2026 14:30 UTC